DBV Technologies S.A. is a biopharmaceutical company that specializes in developing treatments for food allergies. Their innovative approach, using epicutaneous immunotherapy, has shown promising results in clinical trials. With multiple products in their pipeline, DBV Technologies is at the forefront of revolutionizing the management of severe allergic disorders.
